Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gynaecological cancers

3678 - A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study


20 Oct 2018


Poster Discussion session - Gynaecological cancers


Cytotoxic Therapy

Tumour Site

Ovarian Cancer


Antonio Gonzalez


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


A. Gonzalez1, M.R. Mirza2, I. Vergote3, Y. Li4, S. Hazard5, R. Clark5, W. Graybill6, B. Pothuri7, B.J. Monk8

Author affiliations

  • 1 Medical Oncology, Grupo Español de Investigación en Cáncer de Ovario (GEICO) & Clinica Universidad de Navarra, 28036 - Madrid/ES
  • 2 Department Of Oncology, The Nordic Society of Gynecological Oncology (NSGO) & Rigshospitalet–Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 3 Gynecological Oncology, Belgian Gynecological Oncology (BGOG) & University Hospitals Leuven, Leuven/BE
  • 4 Biostatistics, TESARO Inc., Waltham/US
  • 5 Clinical Science, TESARO Inc., Waltham/US
  • 6 Gynecologic Oncology, Medical University of South Carolina, Charleston/US
  • 7 Obstetrics & Oncology, NYU Langone Medical Center, New York/US
  • 8 Gynecologic Oncology, Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3678


Niraparib (Zejula®) is a selective inhibitor of PARP 1/2 approved for maintenance treatment of recurrent ovarian cancer (OC) pts who are in complete or partial response to platinum therapy (plat), regardless of BRCA or HRD status, based on the significantly improved progression-free survival (PFS) for niraparib-treated pts in the pivotal phase 3 ENGOT-OV16/NOVA trial. In NOVA, dose adjustments due to adverse events (AEs) occurred in 69% of pts. Dose adjustments tended to occur early, with most pts reaching their individualized dose within 3 months. A retrospective analysis of NOVA showed that pts with body wt < 77 kg or blplt count <150K/µL were more likely to be dose reduced due to hematologic AEs; efficacy was not compromised in those pts. The PRIMA study evaluates niraparib vs placebo as maintenance therapy in high-risk stage III or IV OC in response to frontline plat therapy. Regular and independent safety data reviews have not identified safety issues in PRIMA. However, the trial was amended to prospectively evaluate the safety and efficacy of a new dosing paradigm.


Plat responsive pts were initially randomized 2:1 to start at niraparib 300 mg qd or placebo. The primary endpoint is PFS. The protocol was amended to require starting dose of 200 mg qd in pts with baseline wt < 77kg or blplt count <150K/µL and 300 mg in all other pts. The trial remains blinded for efficacy and safety.


630 pts are currently enrolled, and 159 pts were dosed based on wt and blplt count. Blinded data were pooled from niraparib and placebo. There were no major differences in key pt demographics or disease characteristics. Key safety data are presented in the table. Data for ≥60 days, ≥90 days, and safety in the overall population will be presented.Table: 941PD

Patients with ≥30 days safety data from blinded pooled niraparib and placebo arms

DosedPre-amendmentPost amendment
N (%)466107
Any TEAE437 (93.8)80 (74.8)
Any related TEAE385 (82.6)70 (65.4)
Any ≥grade 3 TEAE227 (48.7)19 (17.8)
Any serious AE96 (20.6)8 (7.5)
Any grade thrombocytopenia217 (46.6)24 (22.4)
≥Grade 3 thrombocytopenia143 (30.7)6 (5.6)
Any grade anemia191 (41.0)12 (11.2)
≥Grade 3 anemia77 (16.5)3 (2.8)
TEAE leading to end of treatment26 (5.6)2 (1.9)


These interim safety data suggest that niraparib tolerability is improved when dosing is based upon wt and blplt count.

Clinical trial identification


Legal entity responsible for the study

Tesaro, Inc.


Tesaro, Inc.

Editorial Acknowledgement

Writing and editorial support, funded by Tesaro, Inc. (Waltham, MA, USA) and coordinated by Thomas Giove, PhD of Tesaro, Inc., was provided by Nicole Renner, PhD and Dena McWain of Ashfield Healthcare Communications (Middletown, CT, USA).


A. Gonzalez: Grants: Roche; Personal fees: AstraZeneca, PharmaMar, Tesaro, M.R. Mirza: Personal fees: Clovis Oncology, AstraZeneca, Tesaro, I. Vergote: Consulting: GCI Health, Oncoinvent AS, Roche, Genmab, Advaxis, Morphotek, F Hoffman-La Roche, Novocure GMBH, AstraZeneca, Mateon Therapeutics, Immunogen, Eli Lilly Benelux, Amgen, Theradex EU, Pfizer, Debiopharma International, Vifor Pharma Belgie, Novartis, MSD Belgium, Oxigene, Janssen, Nektar Therapeutics, Bayer; Grants: Amgen, Roche; Travel expenses: Tesaro, Theradex, Elsevier, Y. Li, S. Hazard, R. Clark: Employment and stock and other ownership interests: Tesaro Inc, W. Graybill: Consulting or Advisory role: Tesaro, B. Pothuri: Research funding: Tesaro, Caris Life Sciences, Celgene, Clovis Oncology, B.J. Monk: Consulting/Advisory: GSK, Merck, Tesaro, Roche/GNE, AstraZeneca, Gradalis, Advaxis, Verastem, Cerulean, Amgen, Vermillion, Immunogen, Bayer, NuCana BioMed, Insys Therapeutics, Clovis Onc, Oxigene, Pfizer; Speakers bureau: Roche/GNE, AstraZeneca, Janssen, Myriad Genetics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.